News | July 07, 2022
Lonza to build large-scale fill & finish facility in Switzerland
The new facility will be delivered through an investment of approximately CHF 500 million and is expected to be completed in 2026
The new facility will be delivered through an investment of approximately CHF 500 million and is expected to be completed in 2026
This is the 142nd ANDA (including 8 tentative approvals received) out of Eugia Pharma Specialty Group (EPSG) facilities, manufacturing both oral and sterile specialty products.
Company is investing more than €100 million in the expansion of the Halle site
VACUUBRAND has evolved rapidly in recent years, developing new innovative vacuum technology for laboratories, research and engineering
The vaccine is under FDA review
_256_384.jpg){kind=logo}
Meets the growing need for US-based API solubility and bioavailability enhancement services
The investment will enable the company to provide customers with a complete and integrated end-to-end solution
HealthCare Royalty Partners funding supports the ongoing launch of IBSRELA in the United States
The total covered market size of four brands – Z&D, Pediclory, Pecef & Ezinapi combined is Rs 1800 crores
Paliperidone Extended-Release Tablets (RLD Invega) had estimated annual sales of USD 152 million in the U.S
Subscribe To Our Newsletter & Stay Updated
